Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboemboli

1) ClinicalTrials.gov. Cancer Venous Thromboembolism (VTE). Available at:

https://clinicaltrials.gov/ct2/show/NCT0.... [Last accessed: June 2015].

2) Ay C, et al. Prediction of venous thromboembolism in cancer patients. Blood.

2010;116:5377-5382.

3) Khorana AA, et al. Thromboembolism is a leading cause of death in cancer

patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632-634.

4) Mandala M, et al. Management of Venous Thromboembolism (VTE) in Cancer

Patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011:22(6):vi85-vi92.

5) Daiichi Sankyo press release - Daiichi Sankyo Launches New Formulation of

LIXIANA(R) 60 mg Tablets (edoxaban) in Japan. 8 Dec 2014. Available at:

http://www.daiichisankyo.com/media_inves...

. [Last accessed: June 2015].

6) Daiichi Sankyo press release - SAVAYSA(TM) (edoxaban) Now Available in U.S.

Pharmacies. 9 February 2015. Available at:

http://www.daiichisankyo.com/media_inves...

247.html. [Last accessed: June 2015].

7) Daiichi Sankyo press release - Daiichi Sankyo's Once-Daily LIXIANA(R)

(edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular

Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous

Thromboembolism in Switzerland. 15 April 2015. Available at:

http://www.daiichisankyo.com/media_inves...

. [Last accessed: June 2015].

8) Daiichi Sankyo press release - Daiichi Sankyo's Once-Daily Lixiana(R)

(edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic

Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of

Recurrent Venous Thromboembolism in Europe. 27 April 2015. Available at:

http://www.daiichisankyo.com/media_inves...

278.html. [Last accessed: June 2015].

9) Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE) - Blood Clot Forming in

a Vein. Centers for Disease Control and Prevention. Available at:

http://www.cdc.gov/ncbddd/dvt/facts.html... . [Last accessed: June 2015].

10) Van Beek E, et al. Deep Vein Thrombosis and Pulmonary Embolism. New York:

John Wiley & Sons, 2009. Print.

11) Cohen A, et al. Venous thromboembolism (VTE) in Europe. Thromb Haemost.

2007;98(4):756-764.

12) Lee AYY, Levine MN. Venous thromboembolism and cancer: Risks and outcomes.

Circulation. 2003;107:I-17-I-21.

13) Heit JA. The epidemiology of venous thromboembolism in the community.

Arterioscler Thromb Vasc Biol. 2008;28:370-372.

14) Ogata K, et al. Clinical safety, tolerability, pharmacokinetics, and

pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J

Clin Pharmacol. 2010;50(7):743-753.

15) Giugliano R, et al. Edoxaban versus warfarin in patients with atrial

fibrillation. N Engl J Med. 2013;369(22):2093-2104.

16) Büller H, et al. Edoxaban versus warfarin for the treatment of symptomatic

venous thromboembolism. N Engl J Med. 2013;369(15):1406-1415.

Contact

Daria Munsel (Europe)

Daiichi Sankyo Europe GmbH

Edoxaban Comm. & Product PR Europe

+49(89)7808728

Yasuki Minobe (Global)

Daiichi Sankyo Group

Corporate Communication Department

+81(3)62251126